Human Epidermal Growth Factor Receptor 2 (HER2) Antibody Therapy with Lutetium-177 in Patients with Advanced Solid Tumours.
ACTRN 12625000191493 Brief Summary This study is evaluating the safety and properties…
Read more arrow_forwardACTRN 12625000191493 Brief Summary This study is evaluating the safety and properties…
Read more arrow_forwardNCT 06349408 Brief Summary This is a Phase 1 multicenter, multi-regional, open-label,…
Read more arrow_forwardNCT 05872295 Brief Summary This study will evaluate the recommended dose for…
Read more arrow_forwardNCT 03486873 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardNCT 06604533 Brief Summary The aim of this study is to investigate…
Read more arrow_forwardNCT 05735080 Brief Summary Incyclix Bio (Incyclix) is developing INX-315 as an…
Read more arrow_forwardACTRN 12624001340527 Brief Summary This study aims to learn about the safety…
Read more arrow_forwardACTRN 12623000959673 Brief Summary This study is evaluating the safety and properties…
Read more arrow_forwardNCT 06092580 Brief Summary The aims of this clinical trial are (1)…
Read more arrow_forwardNCT 06249048 Brief Summary Phase 1/2, Open-label, Multi-center, First-in-human Study of the…
Read more arrow_forward